Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

This study has been completed.
Information provided by:
Sir Charles Gairdner Hospital Identifier:
First received: September 27, 2006
Last updated: May 22, 2008
Last verified: May 2008
The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.

Condition Intervention
Kidney Failure, Chronic
Drug: Eprex; Neorecormon; Aranesp

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience

Resource links provided by NLM:

Further study details as provided by Sir Charles Gairdner Hospital:

Estimated Enrollment: 150
Study Start Date: September 2006
Study Completion Date: April 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • On haemodialysis at a Sir Charles Gairdner Hospital Unit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00382044

Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Study Director: Neil C Boudville, MBBS Sir Charles Gairdner Hospital
  More Information

Responsible Party: Dr Neil Boudville, Sir Charles Gairdner Hospital Identifier: NCT00382044     History of Changes
Other Study ID Numbers: NB-06-10
Study First Received: September 27, 2006
Last Updated: May 22, 2008

Keywords provided by Sir Charles Gairdner Hospital:
Kidney Failure, Chronic

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Darbepoetin alfa processed this record on May 25, 2017